Compare FEIM & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | AQST |
|---|---|---|
| Founded | 1961 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 504.0M |
| IPO Year | 1994 | 2007 |
| Metric | FEIM | AQST |
|---|---|---|
| Price | $68.32 | $3.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $51.50 | $9.00 |
| AVG Volume (30 Days) | 143.8K | ★ 1.8M |
| Earning Date | 03-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | $21.73 | $49.60 |
| P/E Ratio | $176.63 | ★ N/A |
| Revenue Growth | ★ 26.30 | 0.77 |
| 52 Week Low | $18.63 | $2.94 |
| 52 Week High | $76.07 | $7.55 |
| Indicator | FEIM | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 43.48 |
| Support Level | $43.53 | $3.70 |
| Resistance Level | $76.07 | $4.38 |
| Average True Range (ATR) | 5.11 | 0.15 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 62.83 | 23.86 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.